Propanc Biopharma (PPCB) Stock Price, News & Analysis

Company Overview

Propanc Biopharma, Inc. is a biotechnology company focused on developing novel treatments for solid tumors. The company’s research centers on the use of proenzymes—precursors to digestive enzymes—as a potential therapeutic approach for targeting cancer cells and limiting tumor growth, recurrence and metastasis.

Propanc’s lead product candidate is PRP, an investigational proenzyme therapy being developed primarily for cancers with a high risk of recurrence, including pancreatic, ovarian and colorectal cancers. The company has described PRP as a formulation intended to act on cancer stem cells and other tumor-related mechanisms; its development remains subject to clinical and regulatory evaluation.

Propanc Biopharma was founded in Australia and has operated as a development-stage biotechnology company serving the global oncology market. The company is led by James Nathanielsz, who has served as chief executive officer and has been involved in advancing its proenzyme-based cancer program. Propanc’s activities have primarily consisted of research, preclinical development and clinical planning rather than commercialized pharmaceutical sales.

Key Stats

• Today's Range: $0.56 to $0.67
• 50-Day Range: $0.60 to $2.23
• 52-Week Range: $0.56 to $52.50
• Volume: 192,319 shs
• Average Volume: 5.37 million shs
• Market Capitalization: $1.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Propanc Biopharma Stock Analysis - MarketRank™

Propanc Biopharma scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Propanc Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Propanc Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Propanc Biopharma is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Propanc Biopharma is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Propanc Biopharma has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.78% of the float of Propanc Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Propanc Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Propanc Biopharma has recently decreased by 91.37%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Propanc Biopharma does not currently pay a dividend.

Dividend Growth

Propanc Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Propanc Biopharma this week, compared to 2 articles on an average week.

Search Interest

8 people have searched for PPCB on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Propanc Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.67% of the stock of Propanc Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Propanc Biopharma has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/15/2025
• Today: 9/24/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PPCB
• Previous Symbol: OTCMKTS:PPCB
• CIK: 1517681
• Web: www.propanc.com
• Phone: (139) 882-0780
• Fax: 61 03 9882 9969
• Employees: 2
• Year Founded: 2007

Profitability

• EPS (Trailing Twelve Months): ($24.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$58.92 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -151.28%
• Return on Assets: -109.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.37
• Quick Ratio: 2.37

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $29.94 per share
• Price / Book: 0.02

Miscellaneous

• Outstanding Shares: 2,280,000
• Free Float: 1,625,000
• Market Cap: $1.37 million
• Optionable: Not Optionable
• Beta: 3.52